Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs

Rickard E. Malmström, Brian B. Godman, Eduard Diogene, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Brzezinska, Anna Bucsics, Stephen Campbell, Alessandra Ferrario, Alexander E. Finlayson, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Iñaki Gutiérrez-Ibarluzea, Alan Haycox, Krystyna Hviding, Harald Herholz, Mikael Hoffmann, Saira Jan, Jan Jones, Roberta Joppi, Marija Kalaba, Christina Kvalheim, Ott Laius, Irene Langner, Julie Lonsdale, Sven-Äke Lööv, Kamila Malinowska, Laura McCullagh, Ken Paterson, Vanda Markovic-Pekovic, Andrew Martin, Jutta Piessnegger, Gisbert Selke, Catherine Sermet, Steven Simoens, Cankat Tulunay, Dominik Tomek, Luka Vončina, Vera Vlahovic-Palcevski, Janet Wale, Michael Wilcock, Magdalena Wladysiuk, Menno van Woerkom, Corrine Zara, Lars L. Gustafsson

Open source

DOI: 10.3389/fphar.2013.00039
Published: 2013
Container: Frontiers in Pharmacology
Publisher: Frontiers Media SA
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2013.00039,
  title = {Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs},
  author = {Rickard E. Malmström and Brian B. Godman and Eduard Diogene and Christoph Baumgärtel and Marion Bennie and Iain Bishop and Anna Brzezinska and Anna Bucsics and Stephen Campbell and Alessandra Ferrario and Alexander E. Finlayson and Jurij Fürst and Kristina Garuoliene and Miguel Gomes and Iñaki Gutiérrez-Ibarluzea and Alan Haycox and Krystyna Hviding and Harald Herholz and Mikael Hoffmann and Saira Jan and Jan Jones and Roberta Joppi and Marija Kalaba and Christina Kvalheim and Ott Laius and Irene Langner and Julie Lonsdale and Sven-Äke Lööv and Kamila Malinowska and Laura McCullagh and Ken Paterson and Vanda Markovic-Pekovic and Andrew Martin and Jutta Piessnegger and Gisbert Selke and Catherine Sermet and Steven Simoens and Cankat Tulunay and Dominik Tomek and Luka Vončina and Vera Vlahovic-Palcevski and Janet Wale and Michael Wilcock and Magdalena Wladysiuk and Menno van Woerkom and Corrine Zara and Lars L. Gustafsson},
  year = {2013},
  journal = {Frontiers in Pharmacology},
  doi = {10.3389/fphar.2013.00039},
  url = {https://doi.org/10.3389/fphar.2013.00039}
}

RIS

TY  - JOUR
TI  - Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
AU  - Rickard E. Malmström
AU  - Brian B. Godman
AU  - Eduard Diogene
AU  - Christoph Baumgärtel
AU  - Marion Bennie
AU  - Iain Bishop
AU  - Anna Brzezinska
AU  - Anna Bucsics
AU  - Stephen Campbell
AU  - Alessandra Ferrario
AU  - Alexander E. Finlayson
AU  - Jurij Fürst
AU  - Kristina Garuoliene
AU  - Miguel Gomes
AU  - Iñaki Gutiérrez-Ibarluzea
AU  - Alan Haycox
AU  - Krystyna Hviding
AU  - Harald Herholz
AU  - Mikael Hoffmann
AU  - Saira Jan
AU  - Jan Jones
AU  - Roberta Joppi
AU  - Marija Kalaba
AU  - Christina Kvalheim
AU  - Ott Laius
AU  - Irene Langner
AU  - Julie Lonsdale
AU  - Sven-Äke Lööv
AU  - Kamila Malinowska
AU  - Laura McCullagh
AU  - Ken Paterson
AU  - Vanda Markovic-Pekovic
AU  - Andrew Martin
AU  - Jutta Piessnegger
AU  - Gisbert Selke
AU  - Catherine Sermet
AU  - Steven Simoens
AU  - Cankat Tulunay
AU  - Dominik Tomek
AU  - Luka Vončina
AU  - Vera Vlahovic-Palcevski
AU  - Janet Wale
AU  - Michael Wilcock
AU  - Magdalena Wladysiuk
AU  - Menno van Woerkom
AU  - Corrine Zara
AU  - Lars L. Gustafsson
PY  - 2013
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2013.00039
UR  - https://doi.org/10.3389/fphar.2013.00039
ER  -

APA

Malmström, R. E., Godman, B. B., Diogene, E., Baumgärtel, C., Bennie, M., Bishop, I., Brzezinska, A., Bucsics, A., Campbell, S., Ferrario, A., Finlayson, A. E., Fürst, J., Garuoliene, K., Gomes, M., Gutiérrez-Ibarluzea, I., Haycox, A., Hviding, K., Herholz, H., Hoffmann, M., Jan, S., Jones, J., Joppi, R., Kalaba, M., Kvalheim, C., Laius, O., Langner, I., Lonsdale, J., Lööv, S., Malinowska, K., McCullagh, L., Paterson, K., Markovic-Pekovic, V., Martin, A., Piessnegger, J., Selke, G., Sermet, C., Simoens, S., Tulunay, C., Tomek, D., Vončina, L., Vlahovic-Palcevski, V., Wale, J., Wilcock, M., Wladysiuk, M., Woerkom, M. V., Zara, C., & Gustafsson, L. L. (2013). Dabigatran – a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2013.00039

Source records

crossref · retrieved 2026-09-26T15:32:00.888Z